Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4237 Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumor pAtients (SAUNA trial) – Study protocol for a bi-national, multi-center, open-label, randomised, pragmatic clinical trial

Introduction: Advanced gastroenteropancreatic neuroendocrine tumors (GEP NET) are treated with targeted therapy or peptide receptor radionuclide therapy (PRRT) (177Lu-DOTATATE) upon progression under somatostatin analogues (SSA). SSA are continued life-long in functional NET, but the benefit of SSA continuation in non-functional NET is unclear. Due to ongoing activity of the somatostatin receptor pathway in GEP NET progressing on SSA, we hypothesize an added efficacy of SSA during second-line therapy.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Kuiper J, Borbath I, Dercksen W, Deroose C,

Keywords: somatostatin analogues, SSA, everolimus, sunitinib, peptide receptor radionuclide therapy, PRRT, quality of life, QoL, gastroenteropancreatic neuroendocrine tumor, GEP NET,